The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics DENVER, July 13, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced…

Source

Previous articleCybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy
Next articleLobe Sciences Appoints Gilberto Jesús Mendoza, President of the World Boxing Association, to Advisory Board